CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing

* Age ≥ 18 years old
* At least single haplotype matched (≥ 3/6) family member
* HIV negative
* For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed
* Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance. \*For Cohort A only, an ineligible donor may be used under urgent medical need if the reason for ineligibility was previously present at time of transplant determination.

For Cohort A only, identified recipient with relapsed and/or refractory CD19-positive leukemia

For Cohort B only, iIdentified recipient with relapsed and/or refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:

* Relapsed and/or refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy
* History of prior autologous leukapheresis failure
* History of prior autologous CAR T-cell manufacturing failure
* Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size/low weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis

Eligibility Criteria for Patients: Pre-Treatment Evaluation\*

Inclusion

• MEMCAR19 recipient candidate ≤\<21 years old with rRelapsed and/or refractory CD19-positive leukemia.

\*Due to potential scheduling challenges, all recipients may not be offered the Pre-Treatment Evaluation consent. This will not be counted as a deviation.

Eligibility Criteria for Patients:Treatment

* Age ≤ 21 years old
* Relapsed and/or refractory CD19-positive leukemia\*:

  * Refractory disease (defined as any of the following):

    * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission
    * Refractory disease despite salvage therapy
  * Relapsed disease (defined as any of the following):

    * 2nd or greater relapse
    * Any relapse after allogeneic hematopoietic cell transplantation (HCT)
    * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT

CD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy

* Patient cohorts:

  * Cohort A: patient has previously received a HCT from the selected CAR T-cell donor
  * Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor.
* For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing
* Detectable medullary CD19-positive leukemia
* Estimated life expectancy of ≥ 8 weeks
* Karnofsky or Lansky performance score ≥ 50
* No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms
* If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:

  * ≥ 3 months from HCT
  * have recovered from prior HCT therapy
  * have no evidence of active GVHD within prior 2 months
  * have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion
* Adequate cardiac function: left ventricular ejection fraction ≥ 40% or shortening fraction ≥ 25% (function may be supported by pharmacologic therapy)
* EKG without evidence of clinically significant arrhythmia
* Adequate renal function: creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if \< 2 years of age)
* Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
* Total bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
* No history of HIV infection
* No evidence of severe, uncontrolled bacterial, viral or fungal infection
* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
* For females of child bearing age:

  * Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment AND Not lactating with intent to breastfeed
* If sexually active, agreement to use birth control until 6 months after CAR T-cell infusion
* No history of hypersensitivity reactions to murine protein-containing products
* Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone ≤ 7 days prior to CAR T-cell infusion
* Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))
* Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion

Exclusion Criteria:

NA

主要终点：Maximum tolerated dose of allogeneic, CD19-CAR.CD45RA-negative cells · This phase I study includes dose escalation/de-escalation based on dose limiting toxicity (DLT) assessment to determine the maximum tolerated dose (MTD) of allogeneic, CD19-CAR.CD45RA-negative cells. · 4 weeks after CAR T-cell infusion

• Group A · EXPERIMENTAL · Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
• Group B · EXPERIMENTAL · Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.

This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or refractory CD19-positive leukemia. Primary Objective To determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or refractory CD19-positive leukemia. Secondary Objectives * To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells. * To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells. Exploratory Objectives * To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells. * To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells. * To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs. * To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles. * To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.